Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SHBG | P04278 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20594856 | 1.00 | EPHX2 (0.33) | EPHX2TSHRSHBG | |
| SCHEMBL3053304 | 1.00 | EPHX2 (0.33) | EPHX2TSHRSHBG | |
| SCHEMBL1965395 | 0.85 | — | — | |
| SCHEMBL8366646 | 0.79 | EPHX2 (0.43) | EPHX2TSHRSHBG | |
| Formic Acid SCHEMBL30610134 | 0.78 | — | — | |
| SCHEMBL9359785 | 0.77 | — | — | |
| SCHEMBL18402659 | 0.77 | TSHR (0.37) | EPHX2TSHRSHBG | |
| SCHEMBL18402799 | 0.77 | TSHR (0.37) | EPHX2TSHRSHBG | |
| SCHEMBL17547340 | 0.77 | — | — | |
| SCHEMBL16557012 | 0.77 | TSHR (0.37) | EPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2019-01-24 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604502-B2 | Substituted 5-cyanoindole compounds and uses thereof | KDM1A, KDM5A, KDM1B | EPHX2 2322/4885TSHR 3500/4885SHBG 4333/4885 |
| US-20190023684-A1 | SUBSTITUTED 5-CYANOINDOLE COMPOUNDS AND USES THEREOF | KDM1A, KDM5A, KDM1B | EPHX2 2322/4885TSHR 3500/4885SHBG 4333/4885 |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | EPHX2 1815/4885TSHR 1056/4885SHBG 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.